Bad AI cholesterol vs good AI cholesterol
The Magnificent 7 of Big Tech has recently experienced a staggering drop, losing over $1 trillion in collective market value. This decline is fueled by apprehensions regarding spending on artificial intelligence and rampant inflation. As challenge...

The tech, meanwhile, is getting better. The pricing model for AI is also transiting towards user fees as businesses deploy digital agents to automate processes. Employee-level productivity gains are yet to be converted into overall operational cost-saving and revenue increase. Organisational constraints have more to do with structured change management than with any tech limitation. This barrier should fall as AI adoption rises to most businesses. Companies are now scaling AI across the organisation, instead of keeping them in isolated pilots. More companies are moving towards an agentic workforce that can handle multi-step workflows.
A deep correction in AI valuations will follow - if the tech stops delivering additional productivity gains, spending on AI infrastructure collapses, or if debt costs become unserviceable. None of these outcomes is imminent. Market reaction tends to be exaggerated, and investors will become more discerning about separating good 'AI cholesterol' from bad. Which will be a healthy reset for tech funding.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.